TherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.89 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.